drugset / Trial / NCT02042911
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate safety and efficacy of SyB L-0501 after 2-day intravenous infusion at a dose of 100 mg/m2/day to patients with chronic lymphocytic leukemia.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 100 mg/m2 | Intravenous |